These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 7724818

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
    Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, Lee KS, Jeun SS, Kim MC, Park CK.
    Oncol Rep; 2007 Jun; 17(6):1359-64. PubMed ID: 17487391
    [Abstract] [Full Text] [Related]

  • 5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [Abstract] [Full Text] [Related]

  • 6. [Medulloblastomas--the results after postoperative radiotherapy with and without adjuvant chemotherapy].
    Grabenbauer GG, Löhnert C, Erhardt J, Buchfelder M, Neubauer U, Beck JD, Reitz S, Seyer H, Thierauf P, Fietkau R.
    Strahlenther Onkol; 1993 Apr; 169(4):213-21. PubMed ID: 8488458
    [Abstract] [Full Text] [Related]

  • 7. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A, Perrone MA, Michiara M, Delnevo D, Franciosi V, Di Blasio B, Ceci G, Camisa R, Ardizzoni A, Cocconi G.
    Cancer; 2005 May 15; 103(10):2109-17. PubMed ID: 15803492
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
    Zacharoulis S, Levy A, Chi SN, Gardner S, Rosenblum M, Miller DC, Dunkel I, Diez B, Sposto R, Ji L, Asgharzadeh S, Hukin J, Belasco J, Dubowy R, Kellie S, Termuhlen A, Finlay J.
    Pediatr Blood Cancer; 2007 Jul 15; 49(1):34-40. PubMed ID: 16874765
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic factors in childhood ependymomas.
    Sutton LN, Goldwein J, Perilongo G, Lang B, Schut L, Rorke L, Packer R.
    Pediatr Neurosurg; 2007 Jul 15; 16(2):57-65. PubMed ID: 2132926
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.